HOME >> BIOLOGY >> NEWS
Dana-Farber scientists discover natural blocker of HIV-1 virus

BOSTON--Researchers at Dana-Farber Cancer Institute have identified a protein in Old World monkeys that blocks infection by the human immunodeficiency virus (HIV-1). The finding could lead to improved animal models of AIDS for research and suggests that that a similar molecule known to exist in humans might be exploited for prevention and therapy.

Named TRIM5-alpha, the blocking molecule may be the first example of an innate, previously unknown arm of the immune system that patrols the body for viruses and, if they enter a cell, prevents them from causing harm.

"This is the first glimpse of a form of intracellular immunity made up of natural factors that specifically and potently block retroviruses such as HIV-1," says Joseph Sodroski, MD, senior author of a paper appearing in this week's issue of Nature. The lead author is Matthew Stremlau, a Harvard Medical School graduate student. "Our finding expands our vision of what we might be able to manipulate to block the very early stages of HIV-1 infection," Sodroski says.

Human cells contain a similar TRIM5-alpha protein but it is less effective than the monkey version in blocking HIV-1 infection. It's possible that the potency of TRIM5-alpha differs among individuals because of genetic variations, which may explain why some people infected with HIV progress rapidly to AIDS, while others have remained healthy for decades.

While therapeutic use of the finding remains speculative, says Sodroski, researchers might find ways to increase effectiveness of the human TRIM5-alpha molecule, or, conceivably, administer the more potent monkey version as a therapy.

TRIM5-alpha proteins reside in "cytoplasmic bodies" inside HIV-1 target cells. The discovery begins to shed light on how the virus, once it has breached the cell membrane, uncoats and converts its genetic material, RNA, into DNA for replication. In a key step in the process, the inner core of the virus sheds its capsid
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
25-Feb-2004


Page: 1 2

Related biology news :

1. Kinase backgrounder: Iressa discovery part of major kinase project at Dana-Farber
2. Dana-Farber launches Center for Applied Cancer Science
3. Dana-Farber researchers to lead collaborative smallpox studies
4. Dana-Farber launches NFCR Center for Therapeutic Antibody Research and Engineering
5. DNA lends scientists a hand, revealing new chemical reactions
6. Conference at UH opens doors for new scientists, engineers
7. Wisconsin scientists develop quick botox test
8. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
9. Alaska scientists find Arctic tundra yields surprising carbon loss
10. UAF scientists discover new marine habitat in Alaska
11. Information system to help scientists analyze mechanisms of social behavior

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2020)... ... 27, 2020 , ... CrucialTrak, a global designer and manufacturer of biometric access ... (CEG) to market and sell its complete line of biometric readers and access ... infrastructure optimization solutions . , Brett Mason, CrucialTrak’s Director of Channel Sales for ...
(Date:5/28/2020)... ... May 28, 2020 , ... Actuate Therapeutics, ... their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at ... place virtually on May 29th, 2020. Dr. Benedito Carneiro, Brown University’s principal investigator ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... background and medical screening, announces the launch of a testing service aimed ... safe. The new service is provided by ClearStar’s Medical Information Services (“MIS”) ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... 23, 2020 , ... Kerafast Inc. , developers of ... the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, ... SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., announced today ... 22-24 during the American Association for Cancer Research Virtual meeting. One poster describes ... consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
(Date:6/11/2020)... ... , ... Greffex, a leading genetic engineering company, with the ... vectors, recently announced a key manufacturing agreement with FUJIFILM Diosynth Biotechnologies to produce ... successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including ...
(Date:6/11/2020)... ... 2020 , ... Reducing carbon emissions has been and will continue to be ... market dips, ways to reduce CO2 is something we can’t avoid. , To ... biofuels being produced today are created from recycled cooking oil or crops. Unfortunately, these ...
Breaking Biology Technology:
Cached News: